F8 and hemophilia A: This report describes a descriptive and multivariate analysis of the effectiveness of Kovaltry in children with hemophilia A in the real-world setting, using data from medical chart abstraction and cross-sectional surveys of physicians, patients, and caregivers.<h4>Results</h4>Male patients aged < 18 years with moderate or severe hemophilia A, residing in five European countries and treated with FVIII were studied.